RecruitingPhase 2NCT07523633

Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder

A Randomized, Double-Blind, Placebo-Controlled Trial of Semaglutide for Reducing Cannabis Use in Adults With Cannabis Use Disorder

Sponsor

Anders Fink-Jensen, MD, DMSci

Enrollment

100 participants

Start Date

Apr 30, 2026

Study Type

INTERVENTIONAL

Conditions

Cannabis Use Disorder Cannabis Dependence Cannabis Abuse Cannabis Use Disorders Cannabis Addiction

Summary

The HASHTAG Study is investigating whether the medicine semaglutide can help adults with cannabis use disorder (CUD) reduce their cannabis use. Participants will be randomly assigned to receive either semaglutide or a placebo. The first 50 participants will have functional brain scans (fMRI) to investigate how the brain responds to cannabis-related cues. The main outcome after 20 weeks is whether semaglutide reduces cannabis use compared to placebo. Changes in brain activity in response to cannabis cues will be explored as a secondary outcome.

Eligibility

Min Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called semaglutide for people with cannabis abuse, cannabis addiction, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.